GOOD NEWS FOR CANCER PATIENTS:
Biotechnology company BGM Pharma has entered into a landmark partnership with the South African Nuclear Energy Corporation (NECSA) and the University of Cape Town (UCT), to bring GluCABTM, a new theranostic, to market. A first for South Africa, the deal signifies a breakthrough in cancer diagnosis and treatment.
As the second leading cause of death globally, cancer was responsible for 8.8 million deaths in 2015, and approximately 70% of deaths from cancer occur in low- and middle-income countries; 41,647 deaths were reported in South Africa in 2014. The global burden of cancer will grow by 70% over the next two decades, with an estimated 22 million new cases and 13 million deaths each year by 2032.
Proving that collaboration between the Government and the private sector is not only possible, but can deliver positive results – this really is a good news story for South Africa and is a fundamental step in the fight against cancer.
Drafted and distributed by SIMONSAYS Communications.
To contact on behalf of BGM Pharma:
Melanie Stevens 011 465-9815 ½ 083 303 9667 email@example.com
Julia Christison 011 465-9815 ½ 083 303 9667 firstname.lastname@example.org